**Functional characterization of genetic enzyme variations in human lipoxygenases**

Thomas Horn a,b, Kumar Reddy Kakularam b, Monika Anton a, Constanze Richter c, Pallu Reddanna b,d, Hartmut Kuhn a

a Institute of Biochemistry, University Medicine Berlin—Charité, Charitéplatz 1, D-10117 Berlin, Germany
b Department of Animal Sciences, School of Life Sciences, University of Hyderabad, Gachibowli, Hyderabad 500046, Andhra Pradesh, India
c Institute of Nutrition Technology and Nutrition Chemistry, TU Berlin, Gustav-Meyer-Allee 25, D-13355 Berlin, Germany
d National Institute of Animal Biotechnology, Hyderabad 500046, Andhra Pradesh, India

**Abstract**

Mammalian lipoxygenases play a role in normal cell development and differentiation but they have also been implicated in the pathogenesis of cardiovascular, hyperproliferative and neurodegenerative diseases. As lipid peroxidizing enzymes they are involved in the regulation of cellular redox homeostasis since they produce lipid hydroperoxides, which serve as an efficient source for free radicals. There are various epidemiological correlation studies relating naturally occurring variations in the six human lipoxygenase genes (SNPs or rare mutations) to the frequency for various diseases in these individuals, but for most of the described variations no functional data are available. Employing a combined bioinformatical and enzymological strategy, which included structural modeling and experimental site-directed mutagenesis, we systematically explored the structural and functional consequences of non-synonymous genetic variations in four different human lipoxygenase genes (ALOX5, ALOX12, ALOX15, and ALOX15B) that have been identified in the human 1000 genome project. Due to a lack of a functional expression system we resigned to analyze the functionality of genetic variations in the hALOX12B and hHALOX3E gene. We found that most of the frequent non-synonymous coding SNPs are located at the enzyme surface and hardly alter the enzyme functionality. In contrast, genetic variations which affect functional important amino acid residues or lead to truncated enzyme variations (nonsense mutations) are usually rare with a global allele frequency < 0.1%. This data suggest that there appears to be an evolutionary pressure on the coding regions of the lipoxygenase genes preventing the accumulation of loss-of-function variations in the human population.

**Introduction**

Lipoxygenases (LOXs) are lipid-peroxidizing enzymes that catalyze the dioxygenation of poly-unsaturated fatty acids containing a cis,cis,1,4-pentadiene structure [1]. Together with various oxygen activating enzymes LOXs increase the cellular oxidizing potential by biosynthesizing lipid hydroperoxides, which serve as an efficient source for free radicals unless they are reduced by peroxide reducing enzymes to the corresponding alcohols [2,3]. LOXs are widely distributed in terrestrial life since they occur in bacteria, fungi, lower marine organisms, plants and higher animals [4,5]. In humans six functional LOX genes (ALOX5, ALOX12, ALOX15, ALOX15B, ALOX12B, and ALOX3E) have been identified [1]. The crystal structures of three different mammalian LOX isoforms (human ALOX5, rabbit ALOX15, porcine ALOX15) have been solved [6-8] and despite subtle structural differences there is a high degree of structural similarity between different LOX isoforms. Human LOXs (hLOX) have been implicated in the pathogenesis of cardiovascular and inflammatory diseases as well as in various forms of cancer but the detailed mechanistic basis for their pathophysiological roles is still a matter of discussion [9-12].

In different epidemiological correlation studies genetic variations in hALOX genes have been related to an increased risk of colorectal cancer [13,14], stroke [15], bronchial asthma [16] and...
atherosclerosis [17]. Unfortunately, most of these variations occur either in intronic, in the promoter or in other non-coding DNA regions and thus, functional characterization of these genetic variations is difficult. However, there are scattered reports, in which the functionality of some genetic variations has been studied: (i) A non-synonymous SNP in the hALOX12 gene (rs28395860) has been identified, which leads to a non-conservative Gln261Arg exchange. This mutation has been correlated to the pathogenesis of osteoporosis, breast cancer and schizophrenia [18–20]. Unfortunately, functional data on the recombinant enzyme indicated that this mutation did hardly impact the in vitro enzyme function [21]. (ii) Heterozygous allele carriers of the hALOX15 Thr560Met SNP (rs34210653) have a significant higher risk for coronary artery disease (CAD) [22]. In vitro mutagenesis studies indicated that this amino acid exchange leads to a near null variant of the enzyme and the molecular basis for the loss in enzyme activity has been explored in detail [23]. A similar naturally occurring near null variant (rs61099320) of this enzyme has recently been described but because of its low occurrence frequency no epidemiological correlation study has yet been carried out [24]. (iii) Inactive enzyme variations in hALOX12B and hALOX3E have been associated with a rare skin dysfunction called autosomal recessive congenital ichthyosis (ARCI) [25]. (iv) In a recent report the non-synonymous SNP rs2228065, which leads to a Glu254Lys exchange in hALOX5, was significantly associated with a higher risk of bronchial asthma [26], whereas it was not associated with an increased risk of breast cancer [27]. Unfortunately, no functional data are currently available for this particular enzyme variant.

Completion of the human 1000 Genome project provided an integrated map of genetic variations in 1052 individuals from all over the world [28] and the corresponding database (www.1000genomes.org) also includes a large number of genetic variations in enzymes and receptors of the arachidonic acid cascade. Although this database does not sufficiently cover the genetic diversity in all parts of the world, particularly in Southeast Asia [29], it serves as a suitable source for detailed studies on the functionality of naturally occurring genetic variants of enzymes, hormones, receptors, and structural proteins. The aim of this work was to analyze the functional aspects of non-synonymous coding enzyme variations in four different hALOX genes to find new interesting candidates which have strong functional effects on position- and stereospecificity, catalytic activity, thermostability and structure. Of course it is impossible to analyze all genetic variations and therefore, we mainly focussed on common SNPs with a published frequency and variations which are either non-conservative amino acid exchanges or who affect important amino acid residues. The N-terminal domain of these enzymes has mainly regulatory functions and even N-terminally truncated enzyme variations showed catalytic activity in vitro and therefore we focussed on genetic variations in the catalytic domain of these LOX isoforms. For this study we took advantage of the 1000 Genome Project database and evaluated the functionality of different genetic variations in four hALOX genes employing a combined in silico and in vitro approach, which involves recombinant protein expression, site-directed mutagenesis and computer-based structural modeling. Due to a lack of a functional expression system the genetic variations in hALOX12B and hALOXE3 are discussed on a theoretical basis.

Material and methods

Materials

The chemicals were obtained from the following sources: arachidonic acid (5Z,8Z,11Z,14Z-eicosatetraenoic acid), linoleic acid (9Z,12Z-octadeca-9,12-dienoic acid) and chloramphenicol from Sigma Aldrich (Hamburg, Germany), HPLC standards of 5(±)-HETE, 8(±)-HETE, 11(±)-HETE, 12(±)-HETE, 13(±)-HODE, and 15(±)-HETE from Cayman Chem. (distributed by Biomol, Hamburg, Germany), sodium borohydride from Aldrich (Steinheim, Germany), ampicillin from Life Technologies, Inc. (Eggenstein, Germany), kanamycin and isopropyl-β-thiogalactopyranoside (IPTG) from Carl Roth GmbH (Karlsruhe, Germany). HPLC solvents were ordered from Baker (Deventer, Netherlands) or VWR International GmbH (Darmstadt, Germany). Restriction enzymes were purchased from Fermentas (St. Leon-Rot, Germany). Oligonucleotide synthesis was performed at BioTecx (Berlin, Germany) and DNA sequencing was carried out at Eurofins MWG Operon (Ebersberg, Germany). The E. coli strain XL-1 Blue was purchased from Stratagene (La Jolla, CA), the E. coli strain BL21(DE3)pLysS and the fluorescent dye SYPRO Orange from Invitrogen (Carlshad, California, USA). The EnBase fed batch system was obtained from the company Biosilta (Oulu, Finland).

Methods

Recombinant expression and purification of hALOX15, hALOX5, hALOX12 and hALOX15B

In order to express hALOX15 as a His-tag fusion protein, the coding region of the corresponding cDNA was first amplified by RT-PCR from human blood and then cloned into the pET28b expression vector between the SalI (N-terminal) and HindIII (C-terminal) restriction sites. For the wild-type enzyme and for each mutant a 0.5 l fed batch liquid culture (EnBase, Biosilta) of E. coli BL21(DE3)pLysS was grown overnight at 30 °C until an OD600 of about 15 was reached. Expression of the recombinant protein was then induced by addition of 1 mM IPTG (final concentration) and the culture was kept for 24 h at 23 °C until a final OD600 of 25–30. Bacteria were centrifuged (3,600g, 4 °C, 10 min) and resuspended in 45 ml phosphate buffered saline (PBS). Cells were lysed by sonification, the cell debris was removed by centrifugation (23,000g, 4 °C, 45 min), and the lysis supernatant was loaded onto a 2 ml Ni-NTA agarose affinity column. To remove loosely bound proteins, the column was washed subsequently with 100 mM Tris/HCl, 300 mM NaCl (pH 8.0) containing either 10 or 25 mM imidazole. The His-tagged fusion protein was then eluted with 100 mM Tris/HCl, 300 mM NaCl, 200 mM imidazole (pH 8.0). The elution fractions were desalted and further purified by anion exchange chromatography on a ResourceQ column (6 ml) to electrophoretic homogeneity (purity > 95%). The purified enzyme was stored in 100 mM Tris/HCl, 150 mM sodium chloride in the presence of 10% (v/v) glycerol (pH 8.0) at –80 °C until use. The iron content of the final LOX preparation was measured by atom absorbance spectroscopy on a Perkin-Elmer Life Sciences AA800 instrument equipped with an AS800 auto sampler. The iron content was related to LOX protein that was quantified by spectrofluorimetrically (1 mg/ml pure human ALOX results in an absorbance of 1.6 at 280 nm).

Expression of hALOX12, hALOX15B and hALOX5 variants was carried out as previously described [30–31].

Lipoxygenase activity assays

ALOX activity of the purified LOX preparations was assayed by RP-HPLC quantification of arachidonic acid (AA) oxygenation. Purified enzyme (4 μg) was incubated with 100 μM arachidonic acid for 15 min at 37 °C. The hydroperoxide fatty acids were reduced to the corresponding alcohols using sodium borohydride and the sample was acidified with acetic acid to pH 3. Then 500 μl
of ice-cold methanol was added, protein precipitate was centrifuged (14,000g, 8°C, 10 min) and aliquots of the clear supernatant were injected to RP-HPLC.

Kinetic measurements were performed using an UV-2102 UV/VIS Scanning Spectrophotometer (Shimadzu, Japan) measuring the increase of absorbance at 235 nm. When linoleic acid was used as a substrate 1.6 µg of purified enzyme was incubated with different concentrations of this fatty acid (1–100 µM) in 1 ml PBS and the formation of conjugated dienes was followed at 235 nm over 60 s.

Activity assays for hALOX12, hALOX15B and hALOX5 variants were carried out as previously described [30–31].

LTA4 Synthase activity of hALOX5 was measured using a modified ALOX5 activity assay [31], while 25 µM 5-S–H(p)ETE was used as substrate. The reaction was stopped after 30 min by adding ice-cold methanol to the reaction mix in the ratio of 1:5:1. The total mix was then analyzed by RP-HPLC measuring the formation of conjugated trienes at 270 nm.

### HPLC analysis

HPLC of the LOX products was performed on a Shimadzu LC-20 instrument equipped with an auto sampler recording the absorbance of the effluent at 235 nm. Reverse phase-HPLC was carried out on a Nucleodur C18 Gravity column (Macherey-Nagel, Düren, Germany; 250 × 4 mm, 5 µm particle size) coupled with a guard column (8 × 4 mm, 5-µm particle size). A solvent system of methanol/water/acetic acid (85/15/0.05, by vol) was used at a flow rate of 1 ml/min. Straight phase-HPLC (SP-HPLC) was performed on a Nucleosil 100-5 column (250 × 4 mm, 5 µm particle size) with the solvent system n-hexane/2-propanol/acetic acid (100/4/0.1, by vol) and a flow rate of 1 ml/min. Enantiomers of hydroxylated fatty acids were separated by chiral phase HPLC (CP-HPLC) employing different types of Chiralcel (Daicel Chem. Ind., Ltd.) columns. As mobile phase a mixture of n-hexane/2-propanol/acetic acid at a flow rate of 1 ml/min was used, in which the 2-propanol content was varied for the different positional isomers: 15-HETE: Chiralcel OD column, 5% 2-propanol; 5-HETE: Chiralcel OB column, 4% 2-propanol. 8- and 12-HETE were additionally separated by a solid-phase HPLC and then methylated using diazomethane. Enantiomers of 8-HETE-methylester were separated on a Chiralcel OD column with a solvent system n-hexane/2-propanol/acetic acid (100/4/0.1, by vol) and 12-HETE-methylester enantiomers were separated on a Chiralcel OD column with a solvent system (100/2/0.1, by vol).

### Thermal shift assay (thermal denaturation)

Purified LOX enzyme (3 µM) was incubated with a 2.5-fold molar excess of fluorescent dye SyproOrange® in 20 mM Tris/HCl containing 150 mM NaCl (pH 8.0), total volume 20 µl. The heat denaturation reaction was performed on a Rotor-Gene RG-3000 real-time PCR machine (Corbett Research, Qiagen, Hilden, Germany) heating up the probes from 30 to 95°C at a rate of 0.5°C/s. The fluorescent dye SyproOrange® is quenched in aqueous solutions and becomes detectable after binding to hydrophobic molecules. Thermal unfolding of the protein induces surface exposure of hydrophobic core regions, where the dye is able to bind. Fluorescence intensity was quantified using a FAM/SYBR green filter. The software Rotor-Gene 4.6 was used for calculation of the negative first derivative of the raw data. Figures were generated with SigmaPlot. The melting temperature (Tm) for each mutant was analyzed in 3–4 independent experiments.

### Immuno blotting

To quantify the relative amounts of different hALOX12 and hALOX5 variants in different enzyme preparations, immunoblotting was carried out as previously described using an anti-his-tag antibody [30–31].

### Structural modeling, analysis and amino acid alignment

The crystal structure of the rabbit ALOX15 (PDB: 2POM) was used as template to model the 3D-structure of the human enzyme. The rabbit ALOX15 shares a high degree of amino acid identity (> 80%) with the human ortholog and thus such modeling is plausible. The structure of the stable ALOX5 (PDB: 308Y) was used as for structural analysis of hALOX5 variants. A protein model from the Protein model database (PDB) was used for structural analysis of hALOX5B (PDB code: PM0078035) [32]. The models for hALOX12 and hALOX3 were generated with the homology modeling web server M4T (Albert Einstein College of Medicine, New York USA) [33–34]. The resulting structures were refined using the protein structure refinement server 3Drefine [35]. All structures were then solvated in TIP3P explicit water models and subjected to energy minimization in the program NAMD [36], CHARMM27 [37] force field parameters were used and structures were minimized by 250,000 steps. Model quality estimation was performed with the Qmean quality estimation server [38]. The visualization software program PyMol (Schrodinger, New York, USA) was used for structural analysis and figure preparation. Multiple sequence alignment was performed with the ClustalW2 program (European Bioinformatics Institute, Cambridge, UK) setting default parameters. ALOX sequences were extracted from the NCBI database (Bethesda, USA) and the information about the natural occurring hALOX variations was taken from the 1000 Genome database (www.1000genomes.org).

### Results

#### ALOX15 (human 15-lipoxygenase)

Human ALOX15 consists of 662 amino acids and its sequence was first published in 1988 [39]. In the 1000 Genome database 94 non-synonymous coding variations are described (Table 1). Two of them, Pro617Ser and Thr560Met, have a global allele frequency of > 1% and are therefore classified as SNPs (Table S1). Since it is impossible to test the functional consequences of all existing genetic variants we selected five non-conservative amino acid exchanges (Arg205Gln, Gly422Glu, Gly422Arg, Thr560Arg, and Pro617Ser) in the catalytic domain of the enzyme for more detailed investigations. These mutants together with the wildtype enzyme were recombinantly expressed, purified to apparent

| ALOX isoform | sum | Number of non-synonymous coding variations |
|--------------|-----|------------------------------------------|
|              | SNPs | Rare missense mutations | Nonsense mutations |
| ALOX15       | 94   | 2 | 84 | 8 |
| ALOX5        | 69   | 1 | 68 | 0 |
| ALOX12       | 67   | 2 | 64 | 1 |
| ALOX15B      | 86   | 6 | 76 | 4 |
| ALOX12B      | 69   | 1 | 68 | 0 |
| ALOX3        | 83   | 2 | 75 | 6 |
| Total        | 468  | 14 | 435 | 19 |
homogeneity and characterized with respect to their enzymatic properties.

When we analyzed the structural position of the selected variations in the 3D-structure of the ALOX15 enzyme we found that two variations (Arg205Gln, Pro617Ser) (Fig. 1A) are localized on the enzyme surface with no immediate connection to the active site. In contrast, the Thr560Met and Gly422Glu/Arg are buried deeply inside the protein in close proximity to the active site (Fig. 1A). This localization might explain why these variants (Thr560Met, Gly422Glu) were catalytically silent (Table 2) which is consistent with previous reports [23–24].

The surface exposed mutants (Arg205Gln, Pro617Ser) are similar to the wildtype enzyme, whereas the Gly422Glu variation is different. The negative first derivative is calculated to determine the inflection point (Tm) of the unfolding curve more accurately. (D) Michaelis–Menten kinetics of different hALOX15 variations. The wildtype enzyme and the Pro617Ser, Arg205Gln, Gly422Arg variations follow Michaelis–Menten kinetics whereas the Thr560Met and Gly422Glu variations are catalytically silent.

**Fig. 1.** Genetic variations in human ALOX15 (A) Structural localization of analyzed hALOX15 variations (PDB: 20PM). The N-terminal β-barrel domain is shown as yellow cartoon; the catalytic domain is represented as marine blue cartoon. The amino acid variations are shown as red spheres. (B) Reverse-phase HPLC of hALOX15 wildtype and different genetic variations. The chromatograms show that the wildtype and the Pro617Ser, Gly422Arg, Arg205Gln variations have a major 15- and minor 12- arachidonate oxygenation specificity while the Gly422Glu variation is inactive. The small peaks in the HPLC profile originate from arachidonic acid autoxidation. (C) Thermostability of hALOX15 wildtype and different genetic variations using a fluorescent-based thermodynamic shift assay. The thermal denaturation curve of the Pro617Ser, Arg205Gln, Gly422Arg variations are similar to the wildtype enzyme, whereas the Gly422Glu variation is different. (D) Michaelis–Menten kinetics of different hALOX15 variations. The wildtype enzyme and the Pro617Ser, Arg205Gln, Gly422Arg variations follow Michaelis–Menten kinetics whereas the Thr560Met and Gly422Glu variations are catalytically silent.
that deletion of this residue leads to a loss of catalytic activity [4].

functions as iron ligand and previous mutagenesis studies showed
by the genetic variations, since they had similar kinetic parameters
(Arg205Gln; Pro617Ser; Gly422Arg) were not dramatically impaired
misfolding in the corresponding enzyme variants, which is a
bated with linoleic acid as described in Material and Methods (Puri

Table 2

Relative catalytic activities and melting points of different hALOX15 variations.

| hALOX15 variation ID | Global allele frequency (%) | 15-HETE (%) | Rel. activity (%) | Melting point Tm (°C) |
|-----------------------|----------------------------|-------------|------------------|----------------------|
| wildtype              |                            | 93 ± 4      | 100 ± 6          | 50.0 ± 0.6          |
| Arg205Gln             | rs11568101                 | 0.5         | 89 ± 6           | 50.4 ± 0.1          |
| Arg402Thr             | rs144038526                | 0.1         | 77 ± 2           | 50.3 ± 0.2          |
| Gly422Glu             | rs1690329                  | < 0.1       | 83 ± 4           | n.d.                 |
| Gly422Arg             | rs147238486                |             | 87 ± 2           | 47.6 ± 0.1          |
| Thr560Met             | rs34210653                 | 1.5         | 74 ± 5           | < 2                  |
| Pro617Ser             | rs144326247                | 1.00        | 96 ± 1           | 141 ± 17            |

Purified recombinant hALOX15 wildtype and the different variations were incubated with arachidonic acid as described in Material and Methods (n=4). The amounts for 15-HETE were quantified for each sample, and wild-type 15-HETE formation was set to 100%. Thermal shift assays were performed as described in Material and Methods. The inflection point of the first negative derivative represents the melting point (Tm) of the enzyme variant.

Table 3

Kinetic parameters of different hALOX15 variations.

| hALOX15 variation ID | kcat (s⁻¹) | Km (μM) | R² |
|-----------------------|------------|---------|----|
| wildtype              | 14.4 ± 0.8 | 3.8 ± 1.0 | 0.89 |
| Arg205Gln             | 12.7 ± 1.2 | 1.2 ± 0.8 | 0.84 |
| Gly422Glu             | 9.6 ± 0.7  | 1.7 ± 0.8 | 0.96 |
| Gly422Arg             | 8.2 ± 1.0  | 1.7 ± 0.8 | 0.96 |
| Thr560Met             | 22.4 ± 1.5 | 4.8 ± 1.3 | 0.95 |
| Pro617Ser             | 24.4 ± 1.5 | 4.8 ± 1.3 | 0.95 |

For all LOX enzymes described so far the C-terminal amino acid functions as iron ligand and previous mutagenesis studies showed that deletion of this residue leads to a loss of catalytic activity [4]. In the 1000 Genome database eight nonsense mutations have been identified (Table 1). These genetic variations are likely to encode for truncated and inactive enzyme species and homozygous allele carriers should be completely hALOX15 deficient. Unfortunately, for neither of these nonsense mutations a global allele frequency has been reported suggesting that this mutation was only found once in the 1000 Genome database. In other words, the allele frequency should be <0.1% (Table 51.).

Next we specifically searched in the 1000 Genome database for genetic variations of other functionally important amino acid residues (iron ligands, specificity determinants). All LOXs identified so far carry a redox active metal (iron or manganese) in the active site [1,4] and for hALOX5 His360, His365, His540, His544, and the C-terminal Ile662 constitute the direct iron ligands [6]. Neither of these residues was affected by a genetic variation.

hALOX5 consists of 674 amino acids and its sequence was first published in 1988 [47]. It is the key enzyme in the biosynthesis of leukotrienes [1,48] and converts arachidonic acid (AA) mainly to 55-H(p)ETE. In addition, it catalyzes the dehydration of 55-H(p)ETE to the alkylic epoxide leukotriene A4 (LTA4) which can then be further metabolized by other enzymes (LTA4H, LTC4S, γ-glutamyl transferases, dipetidases) to leukotrienes [1,48]. Leukotrienes (LTs) are pro-inflammatory mediators, which play a role in the pathogenesis of bronchial asthma and allergic rhinitis [1]. In the 1000 Genome database there are 69 non-synonymous coding variations described for hALOX5 (Table 1) but only the hALOX5 Glu254Ly5 (rs2228065) variant has a global frequency >1% and is therefore defined as SNP. We selected seven non-synonymous coding variations in the catalytic domain of this enzyme for more
Table 4
Relative catalytic activities and product specificities of different hALOX5 variations.

| hALOX5 | variation ID | Global allele frequency (%) | 5-HETE (%) | Rel. activity (%)
|--------|--------------|-----------------------------|------------|------------------|
| wildtype |              | 74 ± 1                      | 100 ± 2    |                  |
| Glu254lys rs2228065 | 7.5 | 90 ± 1                      | 58 ± 5     |                  |
| Pro337ser rs28395860 | 0.1 | 85 ± 1                      | 54 ± 1     |                  |
| Ala447ser rs28395869 | 0.0 | 81 ± 1                      | 118 ± 5    |                  |
| Ala549Val rs113388968 | < 0.1 | 84 ± 1                      | 22 ± 1     |                  |
| Pro577Leu rs143439556 | < 0.1 | 89 ± 1                      | 95 ± 4     |                  |
| Thr591Met rs146768497 | < 0.1 | 86 ± 1                      | 130 ± 7    |                  |
| Lys656Gln rs147238486 | 0.0 | 80 ± 2                      | 122 ± 3    |                  |

hALOX5 aliquots of the Co-Sepharose elution fraction 2 containing equal amounts of LOX protein as determined by western blot analysis were used for activity assays (n = 4). The amounts of HETE isomers were analyzed for each sample by HPLC and are used to calculate the catalytic activity of the different enzyme species. The HETO formation of the wildtype was set to 100%.

detailed functional analysis (Table 4). Structural localization of the altered amino acids revealed that except the Ala549Val variation, which is buried deep inside the enzyme, all other variations are localized at the enzyme surface suggesting that they might have only minor effects on enzyme functionality (Fig. 2A). Site directed mutagenesis confirmed this hypothesis since the enzyme mutants exhibited similar reaction specificities and specific dioxygenase activities (Fig. 2B). All mutants converted arachidonic acid to 5-H (p)ETE as the major reaction product (Fig. 2B) and their relative catalytic activities varied between 22% and 130% when compared to the wildtype enzyme (Table 4). The Ala549Val variation (rs113388968) shows the strongest reduction of dioxygenase activity (loss of 78%) and this impairment might be related to its close proximity to the iron ligand sphere [7]. We also analyzed the effect of two genetic variations on the LTA4 synthase activity of hALOX5 and found that it was hardly affected by the two analyzed variations (Glu254lys, Thr591Met) and this is consistent with our data for dioxygenase activity (Table S2).

In contrast to ALOX15, no nonsense variation that leads to the expression of a C-terminally truncated enzyme has been described for hALOX5 in the database (Table 1). Two of them, Gln261Arg (rs28395860) and Asn322Ser (rs434473) have a high global allele frequency < 1% (38.8% and 34.4% respectively) (Table S1). In total we analyzed four selected non-synonymous coding variations in the catalytic domain of the hALOX12 gene (Asp134His, Glu259Lys, Glu621Arg, and Asn322Ser). Structural analysis indicated that all of these amino acid exchanges are located on the enzyme surface and therefore only minor functional effects can be expected (Fig. 3A). In fact, the specific activity of all mutants was comparable (60-109%) to that of the wildtype enzyme (Fig. 3B) and 12-lipoxygenase (p)ETE was always the dominant reaction product for all enzyme variations (Table 5). Interestingly, the Glu261Arg exchange was also found in two Homo Neanderthalensis individuals [51].

One premature stop variation (Arg348stop, rs141346813) leading to a C-terminally truncated enzyme was found in the 1000 Genome database but since no frequency data are given it must be classified as rare enzyme mutation.

Similar to hALOX15 and hALOX5 we specifically searched the 1000 Genome database for genetic variations of other functionally important amino acid residues (iron ligands, position- and enantioselectivity determinants). The catalytic iron ion is coordinated by the residues His360, His365, His540, Asn544, and Ile663. The triad concept is partly applicable for this enzyme [52] and the hALOX12 carries an Ala at the critical enantioselectivity position 403 indicating that it is an S-LOX [41-42]. Neither for the iron coordination nor for the position- (Phe353, Ala417, Ile593) and enantioselectivity determinants (Ala403) has any genetic variation been described (Table S1). As for hALOX15 Arg402 of hALOX12 may play a role for positioning of the fatty acid substrate within the active site [45-46]. Arg402Gln (rs143339715) is a rare enzyme variant of this LOX isoform but the functional consequences of this amino acid exchange have not been explored.

ALOX15B (human 15-lipoxygenase type II)

This enzyme consists of 676 amino acids (Isoform D) and was first discovered in 1997 [53]. 86 non-synonymous coding variations have been identified in the 1000 Genome database and six of them have a global allele frequency > 1% (Table 1): Pro77Ala (rs78230493), Ala311Val (rs148602477), Arg486His (rs9895916), Arg635Gln (rs36730298), Gln656Arg (rs4792147), and Ile676Val (rs7225107) (Table S1). We selected three frequent genetic variations (Arg486His, Gln656Arg and Ile676Val) in the catalytic domain of the enzyme for more detailed characterization. Two of them (Arg486His, Gln656Arg) are located at the enzyme surface and therefore only minor functional effects were expected. In contrast, Ile676 is an iron ligand and Ile676Val exchange might impact the functionality of the enzyme (Fig. 4A). Functional analysis showed that none of the analyzed hALOX15B SNPs dramatically altered the position specificity (Fig. 4B) and specific activity (Table 6) of the enzyme.

Thermal denaturation studies (Fig. 4C) indicated a two-state unfolding curve for all analyzed hALOX15B variations and analysis of the first derivative of the denaturation curves showed that the Ile676Val mutant has a slightly reduced melting temperature (Tm). This data suggest that the Ile676Val exchange destabilizes the enzyme structure to a certain degree. In contrast, the wildtype enzyme, the Arg486His and Gln656Arg mutants have similar melting curves and thus, these mutations did not impact the enzyme structure (Table 6). The basic kinetic constants Km and kcat (Fig. 4D) were similar for the wildtype enzyme and the different
Fig. 2. Genetic variations in human ALOX5 (A) Structural localization of analyzed hALOX5 variations (PDB: 3O8Y). The N-terminal β-barrel domain is shown as yellow cartoon; the catalytic domain is represented as marine blue cartoon. The amino acid variations are shown as red spheres. (B) Reverse-phase HPLC chromatogram of hALOX5 wildtype and different genetic variations. The chromatograms show that the wildtype and the hALOX5 variations are major 5-lipoxygenating enzymes. The Ala549Val variation shows the strongest reduction in catalytic activity but also forms 5-HETE as major oxygenation product.
Fig. 3. Genetic variations in human ALOX12 (A) Structural localization of analyzed hALOX12 variations (hALOX12 model) N-terminal β-barrel domain is shown as yellow cartoon, the catalytic domain is represented as marine blue cartoon. The analyzed amino acid variations are shown as red spheres. (B) Reverse-phase HPLC chromatogram of hALOX12 wildtype and different genetic variations. The RP-HPLC chromatograms show that the wildtype and the hALOX12 variations are 12-lipoxygenating enzymes.
mutants (Table 7) indicating that the mutations had only minor effects on substrate binding and oxygenation rate. There are four premature stop variations described (Table 1) in the 1000 Genome database but neither of them has a global allele frequency of > 1%.

In hALOX15B the catalytic iron is coordinated by His373, His378, His553, Ser557, and the C-terminal Ile676. Interestingly, Ile676Val is a SNP with a global allele frequency of 9.6%, but our activity data indicated the lack of functional consequences for the amino acid exchange (Fig. 4C). hALOX15B exhibits a single position specificity, as it converts arachidonic acid almost exclusively to 15-H(p)ETE [53]. The ortholog enzyme of mice (Alox15b) is an 8-lipoxygenating enzyme, and two amino acids Tyr603 and His604 are responsible for this functional difference [54]. In hALOX15B Asp603 and Val604 are at this position and previous mutagenesis

| hALOX12 variation | Global frequency (%) | 12-HETE (%) | rel. activity (%) | Melting temperature Tm (°C) |
|-------------------|---------------------|-------------|------------------|--------------------------|
| wildtype          | 100 ± 2             | 100         |                  | 7.4 ± 0.3                |
| Asp134His         | rs114985038         | 0.4         | 109 ± 36         | 7.0 ± 0.2                |
| Glu259lys         | rs4987104           | 0.0         | 60 ± 18          | 7.0 ± 0.2                |
| Gin261Arg         | rs1126667           | 38.8        | 91 ± 10          | 7.0 ± 0.2                |
| Asn322Ser         | rs4344473           | 34.4        | 101 ± 23         | 7.0 ± 0.2                |

Recombinant expression of hALOX12 and product HPLC analysis was performed as described in Materials and Methods with crude bacterial lysate supernatant of 5 ml bacterial cultures (n = 5–10 for each variation). LOX content was determined by western blot analysis and HETE formation was correlated to the amount of recombinant protein. The amounts of HETE isomers were analyzed for each sample by HPLC and are used to calculate the catalytic activity of different enzyme species. The HETE formation of the wildtype was set to 100%.

| hALOX15B Variation | Global frequency (%) | 15-HETE (%) | rel. activity (%) | Melting temperature Tm (°C) |
|---------------------|---------------------|-------------|------------------|--------------------------|
| wildtype            | 100 ± 2             | 100         |                  | 7.4 ± 0.3                |
| Arg486His           | rs9895916           | 8.7         | 100 ± 2          | 57.4 ± 0.2               |
| Gin656Arg           | rs52935869          | 38.6        | 104 ± 1          | 56.9 ± 0.2               |
| Ile676Val           | rs7225107           | 10.3        | 94 ± 7           | 55.0 ± 0.3               |
| Ala416Asp           | rs140152561         | 0.1         | n.d.             | n.d.                     |

Purified recombinant hALOX15B wildtype and the different enzyme variations were incubated with arachidonic acid as described in Material and Methods (n = 4). The amounts for 15-HETE were quantified for each sample, and wildtype 15-HETE formation was set to 100%. Thermal shift assays were performed as described in Material and Methods. The inflection point of the first negative derivative represents the melting temperature (Tm) of the enzyme variation.

Table 5

| hALOX12 variation | Global frequency (%) | 12-HETE (%) | rel. activity (%) | Melting temperature Tm (°C) |
|-------------------|---------------------|-------------|------------------|--------------------------|
| wildtype          | 100 ± 2             | 100         |                  | 7.4 ± 0.3                |
| Asp134His         | rs114985038         | 0.4         | 109 ± 36         | 7.0 ± 0.2                |
| Glu259lys         | rs4987104           | 0.0         | 60 ± 18          | 7.0 ± 0.2                |
| Gin261Arg         | rs1126667           | 38.8        | 91 ± 10          | 7.0 ± 0.2                |
| Asn322Ser         | rs4344473           | 34.4        | 101 ± 23         | 7.0 ± 0.2                |

Recombinant expression of hALOX12 and product HPLC analysis was performed as described in Materials and Methods with crude bacterial lysate supernatant of 5 ml bacterial cultures (n = 5–10 for each variation). LOX content was determined by western blot analysis and HETE formation was correlated to the amount of recombinant protein. The amounts of HETE isomers were analyzed for each sample by HPLC and are used to calculate the catalytic activity of different enzyme species. The HETE formation of the wildtype was set to 100%.

| hALOX15B Variation | Global frequency (%) | 15-HETE (%) | rel. activity (%) | Melting temperature Tm (°C) |
|---------------------|---------------------|-------------|------------------|--------------------------|
| wildtype            | 100 ± 2             | 100         |                  | 7.4 ± 0.3                |
| Arg486His           | rs9895916           | 8.7         | 100 ± 2          | 57.4 ± 0.2               |
| Gin656Arg           | rs52935869          | 38.6        | 104 ± 1          | 56.9 ± 0.2               |
| Ile676Val           | rs7225107           | 10.3        | 94 ± 7           | 55.0 ± 0.3               |
| Ala416Asp           | rs140152561         | 0.1         | n.d.             | n.d.                     |

Purified recombinant hALOX15B wildtype and the different enzyme variations were incubated with arachidonic acid as described in Material and Methods (n = 4). The amounts for 15-HETE were quantified for each sample, and wildtype 15-HETE formation was set to 100%. Thermal shift assays were performed as described in Material and Methods. The inflection point of the first negative derivative represents the melting temperature (Tm) of the enzyme variation.

Fig. 4. Genetic variations in human ALOX15B (A) Structural localization of analyzed hALOX15B variations (PMDB: PM0078035) N-terminal β-barrel domain is shown as yellow cartoon; the catalytic domain is represented as marine blue cartoon. The amino acid variations are shown as red spheres. (B) Reverse-phase HPLC chromatogram of hALOX15B wildtype and different genetic variations. The RP-HPLC chromatograms show that the wildtype enzyme and the Arg486His, Gin656Arg, Ile676Val variants are 15-lipoxygenating enzymes, whereas the Ala416Asp mutant is catalytically silent. The small peaks in the HPLC profile originate from arachidonic acid autoxidation. (C) Thermostability of hALOX15B wildtype and different genetic variations using a fluorescent-based thermodynamic shift assay. The thermal denaturation curve of the Arg486His, Gin656Arg, and Ile676Val are similar to the wildtype enzyme, but the profile for the Ala416Asp variant is different indicating structural differences. The negative first derivative is calculated to determine the inflection point (Tm) of the unfolding curve more accurately. (D) Michaelis-Menten kinetics of hALOX15B wildtype and different genetic variations. All analyzed enzyme species follow Michaelis-Menten kinetics.
His398, His403, His578, Asn582, and the C-terminal Ile701 (Table 1). Suggested that the catalytic iron in hALOX12B is coordinated by on the basis of the character of the mutations. Multiple amino acid not able to test the functional consequences of the amino acid Genome database. There are no variations in the database leading synonymous coding variations have been published in the 1000 described in mouse and human skin [55 after delivery [58]. In humans, genetic variants in the hALOX12B homozygous newborn die because of dehydration several hours inactivity of the enzyme SNPs and the wildtype enzyme of this mutant strongly differs from those of the functional active exchange but since Tyr in principle may also function as iron ligand functional consequences of this amino acid exchange have not been studies (Tyr603Asp+His604Val) converted the mice 8-LOX to a 15-lipoxygenating enzyme. In the 1000 Genome database there is a rare natural occurring variation Val603ile (rs192653434) with a global frequency of 0.1% at this position (Table 1) but the functional consequences of this amino acid exchange have not been studied. One might assume that an ile-to-Val exchange represents a conservative mutation and therefore only minor functional effects should be expected, hALOX15B carries an Ala at the critical enantioselectivity determinant and therefore it has been classified as S-LOX [41–42]. Interestingly, there exists a rare genetic variation at amino acid position 416 (rs140152561), which leads to an Ala-to-Asp exchange. In vitro, this mutation causes inactivity of the enzyme (Fig. 4B) and thermal denaturation curve of this mutant strongly differs from those of the functional active SNPs and the wildtype enzyme (Fig. 4C) suggesting that the 3D-structure of the Ala416Asp mutant is severely hampered. To the best of our knowledge this is the first hALOX15B loss-of-function variation that has been published so far. Nevertheless its allele frequency is very low and therefore homozygous carriers of this mutation cannot be expected (Table S1).

**ALOX12B (human 12-lipoxygenase, 12R type)**

This LOX isoform consists of 701 amino acids and was first described in mouse and human skin [55–57]. Sixty nine non-synonymous coding variations have been published in the 1000 Genome database. There are no variations in the database leading to premature stop codons. Since recombinant expression of this particular LOX isoform in bacteria was not successful we were not able to test the functional consequences of the amino acid exchanges. Thus, we judged the probability of functional alterations on the basis of the character of the mutations. Multiple amino acid sequence alignments of many LOXs (see supporting information) suggested that the catalytic iron in hALOX12B is coordinated by His398, His403, His578, Asn582, and the C-terminal Ile701 (Table 1). There is a genetic variation (rs140063508) leading to a His398Tyr exchange but since Tyr in principle may also function as iron ligand via its phenolic OH-group we do not expect functional consequences for this amino acid exchange. A multiple sequence alignment with sequences of 153 LOX enzymes in different species indicated that the first three iron coordination ligands seem to be invariable (His) throughout the LOX enzyme family (data not shown), while the fourth (His, Asn, Ser, or Gly) and the C-terminal ligand (Ile, Val) are variable. The previous finding that Ser, which also contains a hydroxyl group, can function as an iron coordination ligand supports the idea that a His-to-Tyr exchange might only have minor functional effects. Searching the 1000 Genome database we did not find genetic variations for the triad residues or for the enantioselectivity determinants.

hALOX12B knockout mice show a strong phenotype since homozygous newborn die because of dehydration several hours after delivery [58]. In humans, genetic variants in the hALOX12B gene have been related to the development of autosomal recessive congenital ichthyosis (ARCI) [25]. Some of these mutants have been picked up in human 1000 genome project (Table S1), but except for Pro127Ser (rs72842957), which has a global frequency of 1.1%, the others must be classified as rare enzyme mutations. These data are consistent with the fact that ARCI is a rare skin disease (1:200,000–300,000 Europeans and Northern Americans). Unfortunately, the Pro127Ser variant is not expressed in HEK 293 cells and thus, no functional data are currently available [25]. If this variation with its relatively high global allele frequency of > 1% would be a strong inducer of ARCI a much higher prevalence of this skin disease should be expected [25].

### Table 7

**Kinetic parameters of different hALOX15B variations.**

| hALOX15B     | variation ID | kcat (s⁻¹) | Kₘ | R²  |
|--------------|--------------|------------|----|-----|
| wildtype     | –            | 0.18 ± 0.01| 1.2 ± 1.2 | 0.82 |
| Arg486His    | rs9895916    | 0.27 ± 0.02| 2.8 ± 0.8 | 0.98 |
| Gln656Arg    | rs28395869   | 0.25 ± 0.02| 3.7 ± 0.2 | 0.98 |
| Ile676Val    | rs7225107    | 0.12 ± 0.01| 1.0 ± 0.6 | 0.93 |

Purified recombinant hALOX15B wildtype and different variations were incubated with linoleic acid as described in Material and Methods (n = 3). The formation of conjugated dienes was followed by recording the increase in absorbance at 235 nm for 120 s. The resulting turnover rates (kcat) and Michaelis constants (Kₘ) are given. The R square value (R²) represents the accuracy of the hyperbolic equation.

Discussion

LOXs are lipid peroxidizing enzymes and their intracellular activity contributes to the regulation of the cellular redox homeostasis [2–3]. Since the cellular redox state is an important regulator of the gene expression pattern, SNP-induced dysfunction of LOX isoforms is likely to alter the cellular phenotype. To quantify the probability of genetically caused LOX dysfunction we screened the 1000 Genome database for all six human LOX genes and detected more than 450 non-synonymous coding variations (www.1000genomes.org). However, only 14 of them can be classified as SNPs (global allele frequency > 1%) while variations with a lower frequency must be classified as rare enzyme mutations. Functional analysis of eight SNPs throughout the hALOX family showed that except from the previously characterized hALOX15 near-null SNP Thr560Met (rs34210653) all other hALOX
SNPs had similar enzymatic properties (positional specificity, catalytic activity, thermostability) as the corresponding wildtype enzymes. Structural analysis showed that most of the analyzed SNPs are located at the enzyme surface, and therefore only minor effects on enzyme functionality have been predicted (Figs.1–4).

Most of the LOXs carry a catalytic iron at the active site and the C-terminal Ile is required for metal ion coordination in the active site [1,4]. Thus, all genetic variations leading to the introduction of premature stop codons are loss-of-function mutations. So far, 19 nonsense variations have been detected in all six hALOX genes, but neither of them has a global allele frequency > 0.1% indicating that all are rare enzyme mutations.

We found that almost all published hALOX loss-of-function variations have a global allele frequency of < 0.1%. In contrast, all more common variations (SNPs) were without major functional consequences. This finding is consistent with a conclusion drawn previously, that rare SNPs and mutations (global allele frequency < 5%) have a higher tendency to be related to a certain disease and it was suggested that future studies should focus more on them [28,64]. A major problem with such rare genetic variations is that they are often only discovered once or twice in large human populations and their observation is often restricted to one ethnic background, especially in the Asian population, are required to determine the genetic diversity of rare genetic variations in the human population.

We observed that most of the functionally important amino acid residues in the six LOX genes are not affected by genetic variations. Thus, one might conclude that there is an evolutionary pressure on these residues to keep the functionality of these enzymes. Similar predictions were made for other enzymes evaluating the data from these residues to keep the functionality of these enzymes. Similar residues in the six LOX genes are not affected by genetic variations.

A non-synonymous coding SNP in the human 1000 Genome project [28,59]. Although the exact grounds, especially in the Asian population, are required to them [28,64]. A major problem with such rare genetic variations is that rare alleles and it was suggested that future studies should focus more on them [28,64]. A major problem with such rare genetic variations is that they are often only discovered once or twice in large human populations and their observation is often restricted to one ethnic background, especially in the Asian population, are required to determine the genetic diversity of rare genetic variations in the human population.

We observed that most of the functionally important amino acid residues in the six LOX genes are not affected by genetic variations. Thus, one might conclude that there is an evolutionary pressure on these residues to keep the functionality of these enzymes. Similar predictions were made for other enzymes evaluating the data from these residues to keep the functionality of these enzymes. Similar residues in the six LOX genes are not affected by genetic variations.

Thus, all genetic variations leading to the introduction of premature stop codons are loss-of-function mutations. So far, 19 nonsense variations have been detected in all six hALOX genes, but neither of them has a global allele frequency > 0.1% indicating that all are rare enzyme mutations.
N. Fernandez-Fuentes, C.J. Madrid-Aliste, B.K. Rai, J.E. Fajardo, A. Fiser, M4T: a
N. Arora, V.K. Singh, K. Shah, S. Pandey-Rai, Qualitative and Quantitative
M. Walther, R. Wiesner, H. Kuhn, Investigations into calcium-dependent
K. Hofheinz, K.R. Kakularam, S. Adel, M. Anton, A. Polymarasetty, P. Reddanna,
G. Coffa, A.R. Brash, A single active site residue directs oxygenation stereo-
O. Rådmark, B. Samuelsson, Characterization of the human 5-lipoxygenase gene, Adv. Prostaglandin Thromboxane
G. Rådmark, B. Samuelsson, Regulation of the activity of 5-lipoxygenase, a key
G.R. Abecasis, A. Auton, L.D. Brooks, M.A. DePristo, R.M. Durbin,
T. Horn, L. Ivanov, A. Di Venere, K.R. Kakularam, P. Reddanna, M.L. Conrad,
K. Schwarz, M. Walther, M. Anton, C. Gerth, I. Feussner, H. Kuhn, Structural
G. Fürstenberger, H.C. Hennies, Mutation spectrum and functional analysis
K. Schwarz, M. Walther, M. Anton, C. Gerth, I. Feussner, H. Kuhn, Structural
H.K. Tabor, A. Southwick, R. Tabibiazar, S. Sidney, E. Boerwinkle, A.S. Go, C. Iribarren,
T.L. Assimes, J.W. Knowles, J.R. Priest, A. Basu, A. Borchert, K.A. Volcik, M.L. Grove,
A.D. MacKerell Jr., D. Bashford, M. Bellott, R.L. Dunbrack Jr., J.D. Evanseck,
P. Benkert, M. Künzli, T. Schwede, QMEAN server for protein model quality
T. Kim, H.J. Kim, J.K. Park, J.W. Kim, J.H. Chung, Association between
A.R. Brash, W.E. Boeglin, M.S. Chang, Discovery of a second 15S-lipoxygenase
D. Bhattacharya, J. Cheng, 3Dre
M.T. Nelson, W. Humphrey, A. Gursoy, A. Dalke, L.V. Kalé, R.D. Skeel,
A. Chaitnis, S. Adel, M. Anton, I. Wagner, A. Polymarasetty, P. Reddanna,
D. Sun, M. McDonnell, X.S. Chen, M.M. Lakkis, H. Li, S.N. Isaacs, S.H. Elsea,
R. E. Handsaker, H. M. Kang, G. T. Marth, G. A. McVean, G. P. Consortium, An
O. Rådmark, B. Samuelsson, Regulation of the activity of 5-lipoxygenase, a key
K. Schwarz, M. Walther, M. Anton, C. Gerth, I. Feussner, H. Kuhn, Structural
M. Walther, R. Wiesner, H. Kuhn, Molecular basis for the reduced catalytic activity of the naturally occurring T560M mutant of human 15-lipoxygenase that has been implicated in corneary artery disease, J. Biol. Chem. 286 (2011) 23290–23292.
K. Schmidt, M. Walther, A. Fiser, W. Kropp, M. Anton, M. T. Nelson, L. Ivanov, A. Di Venere, K.R. Kakularam, P. Reddanna, M.L. Conrad, C. Richter, P. Scheerer, H. Kuhn, Molecular basis for the catalytically inactive or naturally occurring near-null variant of human ALOX15, Biochim. Biophys. Acta. 835 (2012) 131–136.